![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 16:01 ET
|
Cara Therapeutics
– Phase 3 pivotal trials for I.V. CR845 expected to initiate during second quarter of 2015, following scheduled End-of-Phase 2 Meeting –
– Reported positive top-line data from...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine's 31st Annual Meeting
March 19, 2015 17:00 ET
|
Cara Therapeutics
Pain experts to discuss latest kappa opioid agonist data and the future of pain management
Company to present positive data from Phase 2 trial of I.V. CR845 during poster sessions...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015
March 19, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., March 19, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Webcast Presentation at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference
March 13, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., March 13, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Issued Additional U.S. Patent Covering the Expanded Use of Kappa Opioid Receptor Agonist CR845 and Analogs for the Treatment and Prevention of Pain-Related Conditions
February 10, 2015 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., Feb. 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics to Webcast Presentation at 17th Annual BIO CEO & Investor Conference
February 02, 2015 07:01 ET
|
Cara Therapeutics
SHELTON, Conn., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Announces Addition to the NASDAQ Biotechnology Index
December 18, 2014 08:00 ET
|
Cara Therapeutics
SHELTON, Conn., Dec. 18, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to selectively...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients
December 17, 2014 08:00 ET
|
Cara Therapeutics
I.V. CR845 observed to be safe, well tolerated, and to exhibit dose linear exposure in patients undergoing dialysis
Effective itch reduction seen in subgroup of patients with uremic...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer
December 02, 2014 08:05 ET
|
Cara Therapeutics
SHELTON, Conn., Dec. 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to...
![Cara Therapeutics logo](/news-release/logo/311292/0/311292.jpg?lastModified=12%2F09%2F2016%2023%3A24%3A14&size=2)
Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
December 02, 2014 08:00 ET
|
Cara Therapeutics
All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration
Establishes dosing range and regimen for Phase 2 trial design...